| Literature DB >> 36231545 |
Noelia Rodríguez-Blanco1,2, Nancy Vicente-Alcalde3, Laura Cubero-Plazas4, Jesús Sánchez-Más5, Emilia Montagud6,7, Raul Moragues8, Eva Gabaldón-Bravo9, Jose Antonio Hurtado-Sanchez9, José Tuells10.
Abstract
Healthcare professionals must play an exemplary role in the field of vaccinology. It is convenient that they are trained during their time at university. The objective of this study was to determine the acceptability of the vaccines against COVID-19 in health sciences students in Spanish universities. A cross-sectional study was performed regarding the acceptance of the vaccines against COVID-19 in students in the Health Sciences Degrees in Spanish universities was performed on a sample of students of nursing, medicine, and pharmacy during the spring of 2021, via an online questionnaire with 36 questions designed ad hoc, self-administered, anonymized, and standardized. There were 1222 students participating, of Spanish nationality (97.4%), women (80.5%) and with an average age of 22.0 ± 4.8 years old. Of those, 12.3% had had the disease, 44.0% had to quarantine, 70.8% had undergone diagnostic tests, out of which 14.1% were positive. In total, 97.5% of those surveyed indicated their desire of being vaccinated, if possible, with Comirnaty® (74.9%). At the time of the study, 49.6% were already vaccinated. The reasons for vaccination differed according to the degree and the doubts about vaccine safety was the largest reason for reluctance. Some 37.7% suspected that there are unknown adverse effects and 85.6% of those vaccinated experienced some mild effects after injection. Vaccine acceptance and confidence in the recommendations given by health authorities is high in health sciences students.Entities:
Keywords: COVID-19; acceptability; health sciences; medicine; nursing; pharmacy; students; vaccine
Mesh:
Substances:
Year: 2022 PMID: 36231545 PMCID: PMC9566371 DOI: 10.3390/ijerph191912244
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Demographic characteristics of college students (n = 1222).
| Nursing | Pharmacy | Medicine | Total | IC 95% | ||
|---|---|---|---|---|---|---|
| 716 (52.0) | 124 (11.5) | 382 (36.5) | 1222 (100) | |||
| Sex | ||||||
| Male | 95 (13.3) | 46 (37.1) | 97 (25.4) | 238 (19.5) | (14.5–24.5) | <0.001 |
| Female | 621 (86.7) | 78 (62.9) | 285 (74.6) | 984 (80.5) | (78.0–82.9) | |
| Origin | ||||||
| Spanish | 697 (97.3) | 120 (96.8) | 373 (97.6) | 1190 (97.4) | (96.5–98.3) | 0.867 |
| Not Spanish | 19 (2.7) | 4 (3.2) | 9 (2.4) | 32 (2.6) | (0.0–8.1) | |
| Living arrangement | ||||||
| Alone | 487 (68.0) | 69 (55.6) | 266 (69.6) | 822 (67.3) | (64.1–70.5) | 0.013 |
| With a partner | 229 (32.0) | 55 (44.4) | 116 (30.4) | 400 (32.7) | (28.1–37.3) | |
| Age (years) | 22.2 ± 5.0 | 22.8 ± 5.2 * | 21.6 ± 4.1 † | 22.0 ± 4.8 | ||
| Academic year | ||||||
| Lower | 376 (52.5) | 47 (37.9) | 142 (37.2) | 565 (46.2) | (42.1–50.3) | <0.001 |
| Upper | 340 (47.5) | 77 (62.1) | 240 (62.8) | 657 (53.8) | (50.0–57.6) | |
| Chronic disease | ||||||
| No | 622 (86.9) | 113 (91.1) | 353 (92.4) | 1088 (89.0) | (87.1–90.8) | 0.015 |
| Yes | 94 (13.1) | 11 (8.9) | 29 (7.6) | 134 (11.0) | (5.7–16.3) | |
| Tobacco | ||||||
| No | 609 (85.1) | 109 (87.9) | 345 (90.3) | 1063 (87.0) | (84.9–89.0) | 0.045 |
| Yes | 107 (14.9) | 15 (12.1) | 37 (9.7) | 159 (13.0) | (7.7–18.2) | |
| Alcohol | ||||||
| No | 643 (89.8) | 104 (83.9) | 348 (91.1) | 1095 (89.6) | (87.8–91.4) | 0.070 |
| Yes | 73 (10.2) | 20 (16.1) | 34 (8.9) | 127 (10.4) | (5.1–15.7) | |
| Psychoactive drugs | ||||||
| No | 705 (98.5) | 121 (97.6) | 375 (98.2) | 1201 (98.3) | (97.6–99.0) | 0.767 |
| Yes | 11 (1.5) | 3 (2.4) | 7 (1.8) | 21 (1.7) | (0.0–7.2) |
* p = 0.035 vs Nursing; † p = 0.008 vs Pharmacy (Test U Mann-Whitney). The Chi2 p-value was calculated using contingency tables. Academic year: Lower: 1–2 course and Upper 3–5 course.
COVID-19 disease in surveyed students. (n = 1222).
| Nursing | Pharmacy | Medicine | Total | IC 95% | ||
|---|---|---|---|---|---|---|
| Have you had COVID-19? (n = 1222) | ||||||
| Yes | 100 (14.0) | 15 (12.1) | 35 (9.2) | 150 (12.3) | (7.0–17.5) | 0.069 |
| No | 616 (86.0) | 109 (87.9) | 347 (90.8) | 1072 (87.7) | (85.7–89.6) | |
| Did you catch it at university? (n = 150) | ||||||
| Yes | 4 (4.0) | 0 (0) | 0 (0) | 4 (2.7) | (0–18.6) | 0.527 |
| No | 78 (78.0) | 13 (86.7) | 31 (88.6) | 122 (81.3) | (74.4–88.2) | |
| Don’t know | 18 (18.0) | 2 (13.3) | 4 (11.4) | 24 (16.0) | (1.3–30.6) | |
| Have you had to quarantine? (n = 1213) | ||||||
| Yes | 316 (44.4) | 50 (40.7) | 168 (44.3) | 534 (44.0) | (36.8–51.8) | 0.729 |
| No | 395 (55.6) | 73 (59.3) | 211 (55.7) | 679 (56.0) | (49.0–62.4) | |
| Have any of your family members or friends died from COVID-19? (n = 1222) | ||||||
| Yes | 118 (16.5) | 17 (13.7) | 68 (17.8) | 203 (16.6) | (11.5–21.7) | 0.562 |
| No | 598 (83.5) | 107 (86.3) | 314 (82.2) | 1019 (83.4) | (81.1–85.7) | |
| Have you taken a diagnostic test, antigen test or PCR? (n = 1222) | ||||||
| Yes | 526 (73.5) | 70 (56.5) | 269 (70.4) | 865 (70.8) | (67.7–73.8) | <0.001 |
| No | 190 (26.5) | 54 (43.5) | 113 (29.6) | 357 (29.2) | (24.5–34.0) | |
| What were the results of the antigen test or PCR? (n = 865) | ||||||
| Positive | 77 (14.6) | 13 (18.6) | 32 (11.9) | 122 (14.1) | (7.9–20.3) | 0.307 |
| Negative | 449 (85.4) | 57 (81.4) | 237 (88.1) | 743 (85.9) | (83.4–88.4) | |
p-value = calculated for the Chi-square test group.
Acceptance of the COVID-19 vaccine and attitude towards vaccination. (n = 1222).
| Nursing | Pharmacy | Medicine | Total | IC 95% | ||
|---|---|---|---|---|---|---|
| Would you vaccinate against COVID-19? (n = 1222) | ||||||
| Yes | 695 (97.1) | 120 (96.8) | 377 (98.7) | 1192 (97.5) | (96.6–98.4) | 0.214 |
| No | 21 (2.9) | 4 (3.2) | 5 (1.3) | 30 (2.5) | (0–8.0) | |
| Should there be a choice of COVID-19 vaccine? (n = 1222) | ||||||
| Yes | 434 (60.6) | 73 (58.9) | 208 (54.5) | 715 (58.5) | (54.8–62.1) | 0.142 |
| No | 282 (39.4) | 51 (41.1) | 174 (45.5) | 507 (41.5) | (37.2–45.8) | |
| Which vaccine would you like to be given? (n = 1222) | ||||||
| Comirnaty® | 542 (75.7) | 82 (66.1) | 291 (76.2) | 915 (74.9) | (72.1–77.7) | 0.043 |
| Spikevax® | 57 (8.0) | 13 (10.5) | 41 (10.7) | 111 (9.1) | (3.7–14.4) | |
| Vaxzevria® | 77 (10.8) | 15 (12.1) | 29 (7.6) | 121 (9.9) | (4.6–15.2) | |
| Jcovden® | 40 (5.6) | 14 (11.3) | 21 (5.5) | 75 (6.1) | (0.6–11.5) | |
| Have you received the COVID-19 vaccine? (n = 1222) | ||||||
| Yes | 433 (60.5) | 24 (19.4) | 149 (39.0) | 606 (49.6) | (45.6–53.6) | <0.001 |
| No | 283 (39.5) | 100 (80.6) | 233 (61.0) | 616 (50.4) | (46.5–54.3) | |
| If you have received it, which vaccine did you receive? * (n = 606) | ||||||
| Comirnaty® | 221 (51.0) | 1 (4.2) | 61 (40.9) | 283 (46.7) | (40.9–52.5) | <0.001 |
| Spikevax® | 49 (11.3) | 1 (4.2) | 22 (14.7) | 72 (11.8) | (4.4–19.2) | |
| Vaxzevria® | 163 (37.6) | 22 (91.7) | 66 (44.3) | 251 (41.4) | (35.63–47.5) | |
| Do you have a complete childhood vaccination schedule? (n = 1222) | ||||||
| Yes | 705 (98.5) | 112 (90.3) | 374 (97.9) | 1191 (97.5) | (96.6–98.4) | <0.001 |
| No | 6 (0.8) | 6 (4.8) | 3 (0.8) | 15 (1.2) | (0–6.7) | |
| Don’t know | 5 (0.7) | 6 (4.8) | 5 (1.3) | 16 (1.3) | (0–6.8) | |
| Have you ever had a flu vaccination? (n = 1222) | ||||||
| Yes | 460 (64.2) | 50 (40.3) | 221 (57.9) | 731 (59.8) | (56.2–63.3) | <0.001 |
| No | 256 (35.8) | 74 (59.7) | 161 (42.1) | 491 (40.2) | (35.8–44.5) | |
p-value = calculated for the Chi-square test group. * vaccinated sample.
Figure 1Reasons for the acceptance towards the vaccines against the COVID-19 disease in students of the three degrees.
Figure 2Reasons for the rejection towards the vaccines against the COVID-19 disease in students of the three degrees.
Beliefs and occurrence of adverse effects after the administration of the COVID-19 vaccine. (n = 1222).
| Nursing | Pharmacy | Medicine | Total | IC 95% | ||
|---|---|---|---|---|---|---|
| Does it produce more adverse effects than other vaccines? (n = 1204) | ||||||
| Yes | 61 (8.6) | 39 (15.4) | 16 (9.8) | 116 (9.6) | (4.2–15.0) | 0.132 |
| No | 487 (68.4) | 74 (60.2) | 239 (64.8) | 800 (66.4) | (63.1–69.7) | |
| Don’t know | 164 (23.0) | 30 (24.4) | 94 (25.5) | 288 (23.9) | (18.9–28.8) | |
| Do there exist unknown adverse effects of the COVID-19 vaccine? (n = 1222) | ||||||
| Yes | 266 (37.2) | 59 (47.6) | 136 (35.6) | 461 (37.7) | (33.3–42.1) | 0.026 |
| No | 99 (13.8) | 23 (18.5) | 62 (16.2) | 184 (15.1) | (9.9–20.3) | |
| Don’t know | 351 (49.0) | 42 (33.9) | 184 (48.2) | 577 (47.2) | (43.1–51.3) | |
| Do you trust in the recommendations of the health authorities? (n = 1219) | ||||||
| Yes | 651 (91.2) | 101 (82.1) | 335 (87.7) | 1087 (89.2) | (87.3–91.0) | 0.035 |
| No | 61 (8.5) | 21 (17.1) | 45 (11.8) | 127 (10.4) | (5.1–15.7) | |
| Don’t know | 2 (0.3) | 1 (0.8) | 2 (0.5) | 5 (0.4) | (0–5.9) | |
| After vaccination, have you suffered adverse effects? (n = 606) | ||||||
| Yes | 374 (86.4) | 22 (91.7) | 123 (82.6) | 519 (85.6) | (82.6–88.6) | 0.298 |
| No | 59 (13.6) | 2 (8.3) | 26 (17.4) | 87 (14.4) | (7.0–21.8) | |
| What adverse effects have you suffered? * n = 374, n = 22, n = 123, n = 519 | ||||||
| Pain at injection site | 291 (77.8) | 16 (72.7) | 84 (68.3) | 391 (75.3) | (71.0–79.6) | 0.101 |
| Tiredness | 205 (54.8) | 13 (59.1) | 62 (50.4) | 280 (53.9) | (48.1–59.7) | 0.616 |
| Fever | 174 (46.5) | 17 (77.3) | 62 (50.4) | 253 (48.7) | (42.5–54.8) | 0.018 |
| Generalized muscle pain | 174 (46.5) | 11 (50.0) | 57 (46.3) | 242 (46.6) | (40.3–52.9) | 0.948 |
| Headache | 186 (49.7) | 11 (50.0) | 38 (30.9) | 235 (45.3) | (38.9–51.6) | 0.001 |
| Shivering | 140 (37.4) | 14 (63.6) | 42 (34.1) | 196 (37.8) | (31.0–44.6) | 0.031 |
| Swollen glands | 28 (7.5) | 1 (4.5) | 14 (11.4) | 43 (8.3) | (0.1–15.5) | 0.321 |
| Vomiting | 22 (5.9) | 3 (13.6) | 10 (8.1) | 35 (6.7) | (0.0–15.0) | 0.290 |
| Other | 22 (5.9) | 1 (4.5) | 3 (2.4) | 26 (5.0) | (0.0–13.3) | 0.314 |
p-value = calculated for the Chi-square test group. * Number of vaccinated grouped by degrees.
Proportion of the occurrence of adverse effects depending on the type of COVID-19 vaccine received and multivariate logistic regression analysis.
| Total | Vaxzevria® | Comirnaty® | Spikevax® | Chi2 | Vaxzevria® | Vaxzevria® | |||
|---|---|---|---|---|---|---|---|---|---|
| 519 (100) | 229 (44.1) | 221 (42.6) | 69 (13.3) | ||||||
| Variable | n (%) | n (%) | n (%) | n (%) | OR (95% CI) | OR (95% CI) | |||
| Pain at injection site | |||||||||
| No ( | 128 (24.7) | 62 (27.1) | 52 (23.5) | 14 (20.3) | 0.454 | 1 | 1 | 1 | 1 |
| Yes | 391 (75.3) | 167 (72.9) | 169 (76.5) | 55 (79.7) | 1.59 (0.92–2.73) | 0.095 | 2.40 (1.11–5.18) | 0.026 | |
| Tiredness | |||||||||
| No ( | 239 (46.1) | 77 (33.6) | 119 (53.8) | 43 (62.3) | <0.001 | 1 | 1 | 1 | 1 |
| Yes | 280 (53.9) | 152 (66.4) | 102 (46.2) | 26 (37.7) | 1.04 (0.60–1.78) | 0.892 | 0.71 (0.34–1.49) | 0.361 | |
| Fever | |||||||||
| No ( | 266 (51.3) | 55 (24.0) | 162 (73.3) | 49 (71.0) | <0.001 | 1 | 1 | 1 | 1 |
| Yes | 253 (48.7) | 174 (76.0) | 59 (26.7) | 20 (29.0) | 0.18 (0.11–0.28) | <0.001 | 0.27 (0.13–0.54) | <0.001 | |
| Generalized muscle pain | |||||||||
| No ( | 277 (53.4) | 86 (37.6) | 144 (65.2) | 47 (68.1) | <0.001 | 1 | 1 | 1 | 1 |
| Yes | 242 (46.6) | 143 (62.4) | 77 (34.8) | 22 (31.9) | 0.70 (0.42–1.16) | 0.168 | 0.79 (0.39–1.61) | 0.513 | |
| Headache | |||||||||
| No ( | 284 (54.7) | 94 (41.0) | 143 (64.7) | 47 (68.1) | <0.001 | 1 | 1 | 1 | 1 |
| Yes | 235 (45.3) | 135 (59.0) | 78 (35.3) | 22 (31.9) | 0.68 (0.41–1.13) | 0.140 | 0.62 (0.31–1.25) | 0.183 | |
| Shivering | |||||||||
| No ( | 323 (62.2) | 97 (42.4) | 168 (76.0) | 58 (84.1) | <0.001 | 1 | 1 | 1 | 1 |
| Yes | 196 (37.8) | 132 (57.6) | 53 (24.0) | 11 (15.9) | 0.58 (0.35–0.99) | 0.044 | 0.29 (0.13–0.67) | 0.003 | |
| Swollen glands | |||||||||
| No ( | 476 (91.7) | 211 (921) | 203 (91.9) | 62 (89.9) | 0.829 | 1 | 1 | 1 | 1 |
| Yes | 43 (8.3) | 18 (7.9) | 18 (8.1) | 7 (10.1) | 2.49 (1.06–5.85) | 0.056 | 3.12 (1.05–9.29) | 0.052 | |
| Vomiting | |||||||||
| No ( | 484 (93.3) | 197 (86.0) | 219 (99.1) | 68 (98.6) | <0.001 | 1 | 1 | 1 | 1 |
| Yes | 35 (6.7) | 32 (14.0) | 2 (0.9) | 1 (1.4) | 0.09 (0.02–0.45) | 0.003 | 0.17 (0.02–1.49) | 0.110 | |
p-value = calculated for the Chi-square test group.